



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 78092

**Title:** Risk stratification of primary liver cancer

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05207387

**Position:** Editorial Board

**Academic degree:** DSc, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** South Korea

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-06-07

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-06-07 05:29

**Reviewer performed review:** 2022-06-07 05:39

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

statements

Conflicts-of-Interest: [ ] Yes [Y] No

### **SPECIFIC COMMENTS TO AUTHORS**

Thanks for recommending me as a reviewer. In this Letter to the Editor, author have read an article with title: "Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment". According to the author, the term "risk factors for the development of PLA" in this article could lead to misunderstandings by readers. First, not all odds ratio (OR) values were obtained from the same study. Second, among the risk factors, there was no family history of PLA. Third, untreated chronic hepatitis D virus infection was classified as a moderate risk factor in the analysis of HCC risk factors, with an OR of 3.9. This letter is well written. If minor revisions are made, the quality of the study will be further improved. 1. Please uniform the line spacing of the first row of Table 1. 2. In Table 1, it would be better to write the footnote as "ALT=alanine aminotransferase".



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 78092

**Title:** Risk stratification of primary liver cancer

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03352142

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Full Professor, Statistician

**Reviewer's Country/Territory:** Iran

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-06-07

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-06-09 12:46

**Reviewer performed review:** 2022-06-14 14:25

**Review time:** 5 Days and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

statements

Conflicts-of-Interest: [ ] Yes [Y] No

### **SPECIFIC COMMENTS TO AUTHORS**

Dear author(s) I read your letter on "Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment in World J Gastroenterol 2022; 28(21): 2251-2281 [DOI: 10.3748/wjg.v28.i21.2251] As I can not approve the presented risk stratification for PLC in above mentioned paper, because they did not do any quantitative pooled analysis, my mean is meta analysis, this approach could provide a reliable evidence based on pooling ORs in different published studies, they presented a risk stratification only based on a review on 4 studies as they presented in table 1, that are not so reliable. From this view point I am agree with you; however I am not agree also with your suggestions you presented in your letter; because it is based on guideline that it also is not based on pooled quantitative data analysis, nowadays the results of meta analysis is an essential part for preparing a comprehensive guideline. Also, in a part of your letter you mentioned the presented ORs in above published paper are not from a same study, this point is not correct and it is not needed to be from a same study! In many area of clinical subjects there a different guidelines or risk scores all have their own value such a developed guideline for PCL in china and you mentioned it however a strict decision about it superiority to other ones needs comprehensive comparative studies.



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 78092

**Title:** Risk stratification of primary liver cancer

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03352142

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Full Professor, Statistician

**Reviewer's Country/Territory:** Iran

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-06-07

**Reviewer chosen by:** Li-Li Wang

**Reviewer accepted review:** 2022-07-30 18:17

**Reviewer performed review:** 2022-07-30 18:19

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

**SPECIFIC COMMENTS TO AUTHORS**

No further